US4857533A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method of treatment for autoimmune diseases
Assignee: Teva Branded Pharmaceutical Products R&D Inc
•
Filing: 1988-12-15
•
Granted: 1989-08-15
•
Expires: 2008-12-15
Abstract
Abstract A method of treating a human or animal patient suffering from an autoimmune disease comprises daily administration to such patient of from about 1 to about 100 mg of the narcotic antagonists nalmefene or naltrexone. The nalmefene (6-methylene-6-desoxy-N-cyclopropyl-methyl-14--hydroxydihydronormorphine) or naltrexone (N-cyclopropylmethyl--14-hydroxy-dihydromorphinone) may be administered in equally divided doses from one to four times daily, preferably by the oral route. Parenteral administration may be utilized where suitable.
Inventors
- 👤 Fred P. Sherman
- 👤 David C. Atkinson
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-06 14:34
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/435; A61K31/47; A61K31/485; A61P; A61P29/00; A61P37/00; A61P7/00
Claims Analysis
Total Claims: 11
Claim 1
Independent Claim
33 words
A method of treating a human or animal patient suffering from an autoimmune disease comprising the daily administration to the patient of from about 1 to about 100 mg of nalmefene or naltrexone.
Claim 2
Independent Claim
33 words
A method of treating a human or animal patient suffering from an autoimmune disease comprising the daily administration to the patient of from about 1 to about 100 mg of nalmefene or naltrexone.
Claim 3
Dependent Claim
31 words
A method according to claim 1 wherein said autoimmune disease is selected from the group consisting of systemic lupus erythematosus, rheumatoid arthritis, autoimmune thyroiditis, autoimmune hemolytic anemia, and acute rheumatic fever.
Claim 4
Dependent Claim
23 words
A method according to claim 2 wherein said autoimmune disease is selected from the group consisting of systemic lupus erythematosus and rheumatoid arthritis.
Claim 5
Dependent Claim
17 words
A method according to claim 1 wherein the nalmefene or naltrexone is administered to the patient orally.
Claim 6
Dependent Claim
38 words
A method according to claim 4 wherein the nalmefene or naltrexone is administered to the patient in an oral dosage form comprising a tablet, capsule, caplet or liquid containing from about 0.5 to about 50.0 mg of nalmefene.
Claim 7
Dependent Claim
17 words
A method according to claim 1 wherein the nalmefene or naltrexone is administered to the patient parenterally.
Claim 8
Dependent Claim
24 words
A method according to claim 6 wherein the nalmefene or naltrexone is administered to the patient by the subcutaneous, intramuscular, intravenous or intra-articular routes.
Claim 9
Dependent Claim
22 words
A method according to claim 1 wherein the nalmefene or naltrexone is administered to the patient from one to four times daily.
Claim 10
Dependent Claim
22 words
A method according to claim 8 wherein the nalmefene or naltrexone is administered to the patient from one to two times daily.
Claim 11
Dependent Claim
40 words
A method according to claim 9 wherein 1 mg of nalmefene or naltrexone is administered to a patient twice daily for an initial period, after which the dosage amount is gradually increased to a maximum of 50 mg twice daily.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1992-08-14 | 1993-02-13 | 1993-08-15 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1996-08-14 | 1997-02-13 | 1997-08-15 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2000-08-14 | 2001-02-13 | 2001-08-15 | $7700.00 | Window Closed / Lapsed |